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The functional effects of folate within one-carbon metabolism involve interrelationships with 
vitamin B12, vitamin B6 and riboflavin and related gene-nutrient interactions. These B 
vitamins have important roles throughout life, from pregnancy, through childhood, to middle 
and older age. Achieving optimal nutritional status for preventing folate-related disease is 
challenging, however, primarily as a result of the poor stability and incomplete bioavailability 
of folate from natural food sources when compared with the synthetic vitamin form, folic acid. 
Thus, in European countries, measures to prevent neural tube defects (NTD) have been largely 
ineffective because of the generally poor compliance of women with folic acid supplementation 
as recommended before and in early pregnancy. In contrast, countries worldwide with 
mandatory folic acid fortification policies have experienced marked reductions in NTD.  Low 
vitamin B12 status is associated with increased risk of cognitive dysfunction, cardiovascular 
disease and osteoporosis.  Achieving optimal B12 status can be problematic for older people, 
however, primarily owing to food-bound B12 malabsorption which leads to sub-clinical 
deficiency even with high dietary B12 intakes. Optimising B vitamin intake may be particularly 
important for sub-populations with impaired folate metabolism owing to genetic 
characteristics, most notably the 677C→T variant in the gene encoding the enzyme MTHFR. 
This common folate polymorphism is linked with several adverse health outcomes, including 
stroke, however, recent evidence has identified its novel interaction with riboflavin (the 
MTHFR co-factor) in relation to blood pressure and risk of developing hypertension.  This 
review addresses why and how optimal status of folate-related B vitamins should be achieved 
through the lifecycle. 
 
Introduction 
Folate is required for one-carbon metabolism and is thus essential for important biological 
pathways including DNA and RNA biosynthesis and methylation reactions.  The functional 
effects of folate within the one-carbon network involve close interaction with vitamin B12, 
vitamin B6 and riboflavin. This review will address why these B vitamins are key in human 
health and how optimal status can be achieved. To illustrate the role of these metabolically 
interrelated vitamins through the lifecycle, case studies highlighting their health impacts at 
early, middle and late life will be reviewed. The significant public health challenges in 
achieving optimal nutritional status, and thus potentially preventing folate-related disease, will 
also be considered. 
 
Functional role of folate and metabolic interaction with other B vitamins 
Folates function as cofactors within one-carbon metabolism (Figure 1). This involves the 
transfer and utilisation of one-carbon units in a network of pathways required for DNA and 
RNA biosynthesis, amino acid metabolism and methylation processes. For folate to function 
effectively within this network, it interacts closely with vitamin B12, vitamin B6 and 
riboflavin(1). Reduced folates enter the one-carbon cycle as tetrahydrofolate (THF) which 
acquires a carbon unit from serine in a vitamin B6-dependent reaction to form 5,10 
methyleneTHF. This co-factor form, in turn, is either converted to 5 methylTHF or serves as 
the one-carbon donor in the synthesis of nucleic acids, where it is required by thymidylate 
synthetase in the conversion of deoyxuridine (dUMP) to deoxythymidine (dTMP) for 
pyrimidine biosynthesis, or is converted to other folate co-factor forms required for purine 
biosynthesis. Methylenetetrahydrofolate reductase (MTHFR) is a riboflavin-dependent 
enzyme that catalyses the reduction of 5,10 methyleneTHF to 5 methylTHF. Once formed, 5 
methylTHF is used by methionine synthase for the vitamin B12-dependent conversion of 
homocysteine to methionine and the formation of THF.  Methionine is activated by ATP to 
form S-adenosylmethionine (SAM), which then donates its methyl group to more than 100 
methyltransferases for a wide range of substrates such as DNA, hormones, proteins, 
neurotransmitters and membrane phospholipids, all of which are regulators of important 
physiological processes(1). SAM is typically referred to as ‘the universal methyl donor’ as it is 
used for a great number of methylation reactions; its generation in tissues is dependent on an 
adequate supply of folate and vitamin B12. In summary, effective folate functioning requires 
essential metabolic interaction with vitamins B12, B6 and riboflavin, and therefore, sub-
optimal status of one or more of these B vitamins, or polymorphisms in folate genes, can impair 
one-carbon metabolism, even if folate intakes are adequate. 
 
Health impacts of folate and related B vitamins through the lifecycle 
Folate and the related B vitamins have essential roles in human health. Although the 
preventative role of folate in neural tube defects (NTD) has been the major focus of public 
health efforts worldwide, international research is addressing other roles of folate in early, 
middle and late life and indeed the intergenerational effects of maternal folate status during 
pregnancy in relation to health outcomes in the offspring during childhood and beyond. 
  
Early life: Effects of folate in preconception, pregnancy and offspring health  
Given that folate is essential for cell division and tissue growth, this vitamin plays a particularly 
important role in pregnancy and fetal development. Over 25 years ago it was proven beyond 
doubt that maternal folic acid supplementation in early pregnancy could protect against 
NTDs(2,3) including spina bifida, anencephaly and related defects. NTDs are the most common 
major malformations of the central nervous system and occur as a result of failure of the neural 
tube to close properly in the first few weeks of pregnancy, leading to death of the fetus or 
newborn, or to various disabilities involving the spinal cord.  The conclusive evidence of the 
role of folate in preventing NTD has led to folic acid recommendations for women of 
reproductive age which are in place worldwide(4,5). As will be discussed later in this review, 
however, achieving optimal folate status for preventing NTD can be challenging for individuals 
and populations. Of note, rates of NTD in Ireland are among the highest in the world. A recent 
report from the Food Safety Authority of Ireland shows that there was a large decrease in the 
incidence rate of NTDs in Ireland from the early 1980s (about 3.5 per 1,000 births) to the mid-
1990s; however, the rate has remained relatively stable since then at about 1 per 1,000 births 
(about 80 cases per annum), similar to the UK.  
Apart from its well established role in preventing NTD in very early pregnancy, folate 
has other essential roles throughout pregnancy, with impacts in early life and beyond. The 
importance of folate for pregnancy was in fact recognised in historical reports of the discovery 
of human folate deﬁciency dating back to the early 1930s, when a fatal anaemia of pregnancy 
first described in India was proven to be responsive to treatment with food sources of the 
vitamin(6). Clinical folate deficiency is now known to cause megaloblastic anaemia, a condition 
characterised by immature, enlarged blood cells (reflecting impaired DNA synthesis), which is 
reversible with folic acid treatment(7). In the absence of maternal folic acid supplementation, 
folate-related anaemia of pregnancy has been reported to occur in up to 24% of 
unsupplemented pregnancies in parts of Asia, Africa, and South America and in up to 5% of 
those in well-nourished populations(7). Red blood cell and serum folate concentrations typically 
decrease throughout pregnancy(8), while folic acid supplementation prevents this decline(9) and 
can thus prevent the occurrence of megaloblastic anaemia of pregnancy(10,11). As folate is 
required for the remethylation of homocysteine to methionine, plasma homocysteine is 
invariably elevated with low folate status(12). Elevated homocysteine, in turn, is associated with 
increased risk of a number of pregnancy complications including NTD,(13,14) preeclampsia,(15,16) 
placental abruption,(17) recurrent early pregnancy loss(18) low birth weight and intrauterine 
growth retardation(19). 
As reviewed elsewhere in this journal(20), in addition to protecting against the 
development of megaloblastic anaemia in the mother, there is emerging evidence linking 
maternal folate during pregnancy with offspring neurodevelopment and cognitive function in 
childhood. Evidence in this area is predominantly based on observational studies reporting 
significant associations between maternal folate concentrations, or use of folic acid 
supplements by mothers in pregnancy, and the cognitive performance of children at critical 
stages of childhood(21–23). However, an intervention study from this centre, the Folic Acid 
Supplementation in the Second and Third Trimesters (FASSTT) trial(9), provided a unique 
opportunity to follow up the children of trial participants and found direct evidence of 
beneficial effects of folic acid provided to mothers during pregnancy on the cognitive 
performance of their children at age 3 and 6 years (i.e. as measured by validated tools, the 
Bayley Scales of Infant and Toddler Development and Weschler Preschool and Primary Scale of 
Intelligence, respectively) (24,25). Thus maintaining optimal maternal folate throughout pregnancy, 
well beyond the early period known to be protective against NTD, may be beneficial for brain 
development and functioning in the child.   
The biological mechanism linking maternal folate with the offspring brain is likely to 
involve folate-mediated epigenetic changes related to brain development and function. DNA 
methylation, the most widely studied epigenetic mechanism for gene regulation, is dependent 
upon the supply of methyl donors provided by folate and related B vitamins via SAM(1). Folate 
deficiency could thus lead to aberrant gene expression with consequential health outcomes(26). 
As reviewed elsewhere in this journal, most epigenetic studies in humans have used a candidate 
gene approach to link maternal status of folate, or reported usage of folic acid supplements, 
with DNA methylation in offspring genes involved in folate biology and neurodevelopmental 
processes(20). The only randomised trial to date to investigate the effect of maternal folic acid 
was carried out at this centre and showed that folic acid supplementation through trimesters 2 
and 3 of pregnancy resulted in significant changes in DNA methylation in cord blood of LINE-
1 and candidate genes related to brain development, IGF2 and BDNF(27). Likewise, animal 
studies found that folic acid supplementation throughout pregnancy significantly increased 
brain folate concentrations in the newborn pups, while brain global DNA methylation 
decreased(28). The findings offer a potential biological basis to link maternal folate status with 
neurodevelopment of the offspring, but this requires further investigation using a genome-wide 
approach to more thoroughly explore the role of DNA methylation in mediating these effects. 
Apart from maternal folate status during pregnancy, the child’s folate status also will 
have important health impacts.  Folate biomarkers in children are reported to decline 
progressively with age in British and American children, possibly indicating that folate 
requirements of older children are higher to sustain the increased metabolic demands for 
growth from childhood to adolescence(29,30). Such findings have not been taken into 
consideration in setting current folate recommendations for adolescents, but should perhaps be 
considered by future panels tasked with evaluating the evidence to support dietary reference 
values for folate in this population sub-group.  
 
Middle age: Effects of MTHFR and riboflavin on blood pressure and hypertension 
Optimal B vitamin intake may be particularly important for sub-populations with impaired 
folate metabolism owing to genetic characteristics, most notably the 677C→T variant in the 
gene encoding the enzyme MTHFR. Since this common folate polymorphism was first 
described over 20 years ago, it has been linked with several adverse health outcomes, including 
stroke(31). Although the health concerns in relation to this polymorphism have predominantly 
focussed on the well described homocysteine phenotype, arguably of greater relevance to 
public health is the more recent emergence of a blood pressure phenotype, and a modulating 
role of riboflavin (MTHFR co-factor), in determining the risk of hypertension(31).  
Hypertension is a significant health concern because it is the leading risk factor 
contributing to mortality worldwide, accounting for 17% of all deaths (9.4 million each year), 
most notably from cardiovascular disease (CVD), with 45% of deaths from heart disease and 
51% of deaths from stroke estimated to result from hypertension(32,33). Reducing blood pressure 
is however proven to decrease CVD(34) and it is estimated that lowering of systolic BP by as 
little as 2 mmHg can decrease cardiovascular risk by as much as 10%(35). The risk of 
hypertension increases with age and occurs as a result of a complex interaction of lifestyle, 
dietary and environmental factors. Genetic factors are also implicated in the development and 
progression of hypertension. Of note, a region near the gene encoding the folate-metabolising 
enzyme MTHFR has been identified by genome-wide association studies (GWAS) among a 
small number of loci associated with blood pressure in European, American and Asian 
populations(36,37). Epidemiological studies have also linked this folate gene with blood pressure, 
with the 677C→T polymorphism in MTHFR estimated to increase the risk of hypertension by 
up to 87% (38), and CVD by up to 40%(39).  However, there is large geographical variability in 
estimates of the excess risk of CVD owing to this polymorphism(31), suggesting the 
involvement of a gene-environment interaction. Folate only was previously considered as the 
relevant environmental factor, but evidence from our centre suggests that riboflavin may be a 
more important modulating factor via a novel effect on blood pressure(31). 
Riboflavin (vitamin B2) plays an important role in folate recycling within one-carbon 
metabolism where it acts in the form of flavin adenine dinucleotide (FAD) as a cofactor for 
MTHFR, the enzyme which catalyses the conversion of 5,10 methyleneTHF to 5 methylTHF; 
the latter co-factor then serves as the methyl donor in the B12-dependent re-methylation of 
homocysteine to methionine (by methionine synthase). The role of riboflavin within the one-
carbon metabolic network is often overlooked in human health, but it is most evident in 
individuals with the homozygous mutant 677TT genotype in MTHFR, resulting in a 
thermolabile enzyme with reduced activity(40). The decreased activity of the variant MTHFR 
enzyme was demonstrated in molecular studies to be the result of a reduced affinity for its FAD 
cofactor(41,42).  In human studies, individuals with the MTHFR 677TT genotype typically 
present with elevated plasma homocysteine(40), along with low folate concentrations (43). The 
homocysteine phenotype is known to be most pronounced if the TT genotype occurs in 
combination with poor nutritional status of either folate (44) or riboflavin(45,46).  Furthermore, 
riboflavin supplementation results in marked lowering of homocysteine concentrations in 
individuals with the TT genotype, but not in those with CC or CT genotypes(47), suggesting that 
enhancing riboflavin status may stabilise the variant enzyme and thus restore MTHFR activity 
in vivo. 
Recent studies indicate that riboflavin interacts with MTHFR to influence blood 
pressure and hypertension risk(31).  We have been studying the modulating effect of riboflavin 
on blood pressure in hypertensive patients (with and without overt CVD) pre-screened for 
MTHFR genotype and published three randomised trials to date showing that the blood pressure 
phenotype is highly responsive to lowering by intervention with riboflavin(48–50). In the first of 
these trials, we investigated a cohort of over 400 premature CVD patients with a mean age of 
53 years (and 47 years at time of event)(48). At baseline, patients with the variant TT genotype 
had significantly higher systolic and diastolic blood pressure compared to their age-matched 
counterparts with CC or CT genotypes, with mean systolic/diastolic blood pressure (mmHg) 
of 131/80, 133/83 and 143/86 for CC, CT and TT genotypes, respectively. Of greater note, 
riboflavin supplementation (1.6 mg/d for 16 weeks) resulted in significant blood pressure-
lowering in patients with the TT genotype, but no effect in those with CC or CT genotypes(48). 
When these high-risk patients were followed up 4 years later, those with TT genotype were 
again found to be hypertensive, despite marked changes in the number and type of 
antihypertensive drugs being prescribed (following changes in clinical guidelines for 
hypertension since the initial investigation), and target blood pressure was again achieved only 
in response to riboflavin(49). In a third trial, we demonstrated that the responsiveness of blood 
pressure to riboflavin intervention in the genetically at-risk group was not confined to high-
risk CVD patients but was also achievable in hypertensive adults without overt CVD(50).  At 
baseline, despite being prescribed multiple classes of antihypertensive drugs, over 60% of 
participants with this genotype had failed to reach target blood pressure (≤140/90mmHg), but 
riboflavin supplementation for 16 weeks (when antihypertensive drugs remained unchanged) 
resulted in a significant decrease in blood pressure(50).  
These randomised trials show that riboflavin has a novel and genotype-specific role in 
lowering blood pressure (by an average of 6 to 14 mmHg in systolic blood pressure), which 
occurs independently of antihypertensive medication(48–50). Furthermore, antihypertensive 
therapy as currently prescribed (typically, polytherapy with 2 or more drugs used in 
combination) appears to be associated with poorer blood pressure control in patients with the 
MTHFR 677TT genotype, while the achievement of target blood pressure can be greatly 
enhanced with supplemental riboflavin at the dietary range of 1.6 mg/d. Given recent calls for 
more personalised approaches to lower blood pressure and thus improve cardiovascular 
health(34), there are clinical and public health implications arising from the finding that the 
under-recognised blood pressure phenotype associated with this common folate polymorphism 
is modifiable by riboflavin. For hypertensive patients with the MTHFR 677TT genotype, 
supplementation with riboflavin could offer a personalised, non-drug treatment to lower blood 
pressure. For sub-populations worldwide, enhancing riboflavin status could prevent or delay 
the development of high blood pressure in those with this genetic risk factor.  Mechanistic 
studies are however required to elucidate the precise link between one-carbon metabolism and 
blood pressure and to understand the biological perturbation leading to higher blood pressure 
in the TT genotype and how riboflavin corrects it. Randomised trials investigating the role of 
this novel gene-nutrient interaction in hypertension through the lifecycle are also required. In 
any case, at this time while other genetic factors appear to play a role in the development of 
hypertension(36,37), the common 677C→T polymorphism in MTHFR is the only genetic factor 
linked with hypertension that offers a personalised management option, via optimising 
riboflavin, the MTHFR co-factor. 
Older age: Effects of folate and related B vitamins on the ageing brain 
Dementia and depression are recognised as major disorders of ageing with profound human(51) 
and economic(52–54) costs. Dementia affects an estimated 46.8 million people worldwide, with 
projections that this will increase to over 131 million people by 2050(52). Cognitive function 
typically declines with age, but in some cases the decline occurs at a greater rate than expected, 
ranging in severity from relatively minor slips in performing activities, through to subjective 
cognitive decline, mild cognitive impairment (MCI) and dementia(55). Activities of daily living 
are profoundly affected in dementia, whereas in MCI, although cognitive decline is greater than 
expected for an individual's age and education level, there is no notable interference in activities 
of daily life, albeit 50% of those with MCI can be predicted to develop dementia within 5 
years.(56) Depression is the most frequent psychiatric disease, and ‘late–life depression’ is 
reported more commonly in females, affecting an estimated 28% of females compared with 
22% of males, over the age of 65 years(57). In addition, depression has been shown to increase 
cognitive dysfunction, while poorer cognitive health can also predispose older adults to 
depression(58,59), suggesting a bi-directional relationship between the two conditions. A recent 
comprehensive report identified a model of modifiable risk factors for dementia across the 
lifespan, highlighting the potential for effective prevention through early interventions that 
target these risk factors(28). In this context, as recently reviewed extensively in this journal(60), 
nutrition can play an important preventative role, with emerging evidence linking certain 
dietary patterns (particularly the ‘Mediterranean’ diet) or specific dietary components, 
including omega-3 polyunsaturated fatty acids, polyphenols, vitamin D and particularly B-
vitamins, with a reduced risk of dementia and depression.  
Folate, vitamin B12 and vitamin B6 play important roles in the nervous system at all 
ages, from neural development in early life through to the maintenance of mental health and 
cognitive function in older age. Thus B vitamin deficiencies can manifest with significant 
neurological and neuropsychiatric disturbances. Historically, deficiencies of folate(61,62) and 
vitamin B12(63,64) have been linked with psychiatric illness and poorer mental wellbeing. The 
reported neuropsychiatric effects of deficiency of either nutrient include cognitive decline, 
depression and peripheral neuropathy, although the latter is more commonly found in vitamin 
B12 deficiency(65).  Folate and vitamin B12 are required for the activity of methionine synthase 
within one-carbon metabolism and therefore the synthesis of SAM, which in turn provides 
methyl groups for numerous central nervous system methylation reactions involving 
neurotransmitter and membrane phospholipid synthesis and myelin methylation(66,67). Thus, 
with folate or vitamin B12 deficiency, the reduction in tissue levels of SAM may contribute to 
cognitive dysfunction by impairing these methylation processes. Reduced tissue concentration 
of SAM may be linked to depression through perturbing monoamine (serotonin, dopamine and 
noradrenaline) synthesis and methylation(68). Additionally, vitamin B6 plays an essential role 
in transamination and decarboxylation reactions, which in turn are involved in neurotransmitter 
synthesis, metabolism and release; deficiency of vitamin B6 is associated with deficits in nerve 
conduction(69). The metabolism of homocysteine requires folate along with vitamin B12, and 
to a lesser extent vitamin B6; when the status of these vitamins is low or deficient, plasma 
homocysteine concentration will invariably be elevated.  Homocysteine concentrations are 
typically higher in patients with Alzheimer’s disease (the most common form of dementia), 
and are strongly related to the rate of cognitive decline in patients with mild cognitive 
impairment and Alzheimer’s disease(68,70) Thus, there has been considerable interest in plasma 
homocysteine as a potential risk factor for cognitive dysfunction, but it remains unconfirmed 
whether homocysteine is a true disease risk factor or merely a marker. In any case however, 
homocysteine measurement provides a sensitive functional biomarker of folate and related B-
vitamin status, and plasma homocysteine shows significant lowering in response to B vitamin 
intervention(1). 
Lower status of folate, vitamin B12 and /or vitamin B6 (or a higher concentration of 
the related metabolite homocysteine) is associated in observational studies with cognitive 
dysfunction(68). Observational data supporting a role for these nutrients, or any nutritional 
factor, can however be complicated by the fact that poor diet may be both a cause and a 
consequence of impaired cognitive function. Only randomised trials can confirm whether a 
causative relationship exists. Although several randomised controlled trials have investigated 
the potential benefits of B-vitamin supplementation on cognitive function, many of these were 
of insufficient duration to provide clear evidence, while others intervened in patients with 
confirmed Alzheimer’s disease where a beneficial effect is highly unlikely. One well designed 
randomised trial of healthy older adults in New Zealand reported no benefit of high dose 
combined folic acid/vitamin B12/vitamin B6 for two years on any cognitive function parameter 
examined(71), whereas another similar study from the Netherlands showed that supplementation 
with folic acid alone for three years significantly improved a number of cognitive parameters 
including memory, information-processing speed and sensorimotor function(72).  An important 
difference between these two studies was baseline folate status which was far lower in the 
Dutch trial(72), suggesting that any benefit of folic acid on cognitive function arises through 
correction of sub-optimal folate status, whereas providing additional folic acid to those with 
already optimal status may have no effect on cognition. More recent randomised trials, showing 
that intervention with B vitamins prevented cognitive decline in free-living older adults with 
depressive symptoms, or improved cognitive performance in participants with mild cognitive 
impairment, provide convincing evidence that low B vitamin status may be causatively linked 
with cognitive dysfunction in ageing. Research in this area has been very substantially 
underpinned by the work of Smith and colleagues on the VITACOG trial which showed that B 
vitamin intervention not only improved cognitive performance(73), but also slowed the rate of 
global and regional brain atrophy as determined using magnetic resonance imaging (MRI) in 
participants with mild cognitive impairment (74,75).  Not all studies support the role of B 
vitamins, however, and one notable meta-analysis concluded that there was no beneficial effect 
of either folic acid or vitamin B12 on cognition in older adults(76).  The latter report has however 
been widely criticised by experts in this area, primarily owing to the inclusion criteria used to 
select the trials for investigation in the meta-analysis(77,78).  
Apart from memory deficits and cognitive dysfunction, depressive symptoms are well 
described in both folate and vitamin B12 deficiency(65).  Furthermore, folate deficiency can 
affect the duration and clinical severity of depression, and is associated with poorer response 
to antidepressant medication(65).  Low folate status was associated with a significantly greater 
risk of depression in one meta-analysis of  observational studies(79).  Likewise, low 
concentrations of vitamin B12(80–82) and vitamin B6 (required as a cofactor in the metabolism 
of tryptophan and serotonin)(83,84) have also been linked with depression. Randomised trials, 
investigating the role of B-vitamin supplements alone or as an adjunct to anti-depressant 
medications, have however produced conflicting results. The balance of available evidence in 
this area would appear to suggest that folate and vitamin B12 may have roles in the longer-
term management of depression(85,86).  
Overall, there is good evidence to suggest that optimal B vitamin status has protective 
effects on cognitive function, and potentially against depressive symptoms, in ageing(60).  To 
address the gaps in the evidence-base in this area, however, appropriately designed randomised 
trials are required, targeting participants with low B-vitamin status and thus most likely to 
benefit from optimising B-vitamin status to achieve better cognitive and mental health in 
ageing.  
 
Considerations and challenges in achieving optimal status of B vitamins 
Folate  
Folic acid refers to the synthetic form of the B vitamin known as folate, whereas the natural 
folate forms are found in plant, animal and human tissues. Food folates occur naturally in 
richest supply in green leafy vegetables, asparagus, beans, legumes, liver and yeast. Folic acid 
is found in the human diet only in fortified foods and supplements but is readily converted to 
the natural cofactor forms of folate after its ingestion(87). There are however chemical 
differences between folic acid and the natural folate forms which have important nutrition 
consequences. Folic acid is a fully oxidised molecule and is a monoglutamate, meaning that it 
contains just one glutamate moiety in its structure. Naturally occurring food folates on the other 
hand are a mixture of reduced folate forms (predominantly 5 methyTHF) and typically found 
as polyglutamates, containing a variable number of glutamate residues(88). As reduced 
molecules, natural food folates are inherently unstable outside living cells and tend to have 
poor bioavailability(87).  In addition to their limited bioavailability, food folates (particularly 
green vegetables) can be unstable during cooking, and this will substantially reduce the folate 
content of the food before it is even ingested(89). Folic acid is more stable and more bioavailable 
compared to an equivalent amount of the vitamin eaten as naturally occurring food folates(87). 
As a result of the poor stability and limited bioavailability of folate from natural food sources, 
achieving optimal folate status is challenging for individuals and populations.  
It is important to appreciate that the absence of folate deficiency (i.e. megaloblastic 
anaemia) does not necessarily mean that folate status is optimal in terms of maintaining health 
and preventing folate-related disease such as NTD. Thus in many developed countries folate 
deficiency may be relatively rare, but sub-optimal folate status is commonly encountered(1). 
Folate status and response to intervention are routinely assessed by measuring folate 
concentrations in serum/plasma or in red blood cells(90,91). Serum folate reflects recent dietary 
intake and is the earliest indicator of altered folate exposure(92). Red blood cell folate parallels 
liver concentrations (accounting for about 50% of total body folate) and is thus considered to 
represent tissue folate stores(93). Compared with serum folate, red blood cell folate responds 
slowly to changes in dietary folate intake and is a better indicator of folate intake over the 
previous 3-4 months, when circulating folate is incorporated into the maturating red cells(92,94). 
On the basis that homocysteine metabolism requires an adequate supply of folate, the 
measurement of plasma homocysteine provides a functional biomarker of folate status and is 
invariably found to be elevated with low or deficient folate status.   
Folate intakes and recommendations in the United States and certain other countries are 
now expressed as Dietary Folate Equivalents (DFEs), a calculation which was devised to take 
into account the greater bioavailability of folic acid from fortified foods compared to naturally 
occurring dietary folates(95,96). Specifically for the prevention of NTD, women are 
recommended to take 400 g/d folic acid as a supplement from preconception until the end of 
the first trimester of pregnancy(4,5). Folic acid supplementation is a highly effective means to 
optimise folate status in women if the recommendations are followed(97,98).  However, it is not 
an effective public health strategy for populations because in practice very few women take 
folic acid as recommended before and in early pregnancy and this means that maternal 
biomarker status of folate is often found to be suboptimal in achieving concentrations known 
to be protective against NTD(98,99). Fortification of food with folic acid, like supplementation, 
is very effective in optimising dietary intake and biomarker status of folate in those who choose 
to eat fortified food products(100,101). However, fortification has the advantage over 
supplementation that it can also be highly effective for populations. When folic acid 
fortification is undertaken on a population-wide basis (via a policy of mandatory fortification), 
it results in significant increases in folate biomarker concentrations and marked reductions in 
NTD(1). Thus reported rates of NTD have declined by between 27% and 50% in the USA, 
Canada and Chile in response to mandatory folic acid fortification of food(102–104).  In contrast, 
in the UK, Ireland and other European countries, policy to prevent NTD (i.e. based on folic 
acid supplementation) has had little or no impact in preventing NTD, despite active health 
promotion campaigns over many years(105,106).  This is primarily because the neural tube closes 
by day 28 post-conception and therefore the timing of folic acid usage by women is critical. 
For many women, the early period of pregnancy when folic acid is protective against NTD may 
have passed before folic acid supplements are started. This has resulted in an unacceptably high 
rate of NTD in European countries, recently estimated to be 1.6 times higher than in regions of 
the world with mandatory folic acid-fortification policies in place(107).  Of particular concern 
are reports that the incidence of NTD in Ireland is increasing in recent years(108). 
Over 80 countries worldwide to date (including the United States, Canada and 
Australia) have passed regulations for the mandatory fortification of staple foods with folic 
acid in order to prevent NTD. Other countries including the UK and Ireland have delayed 
decisions to introduce mandatory fortification on the basis of concerns relating to possible 
health risks. Once ingested, folic acid is reduced by dihydrofolate reductase (DHFR) and 
methylated, then released into the systemic circulation as 5 methylTHF. However, the capacity 
of DHFR in humans to efficiently metabolise folic acid is limited and thus exposure to high 
oral doses can result in the appearance of unmetabolised folic acid in plasma(1). On the basis 
that the latter is not a normal constituent of plasma or other tissues, concerns have arisen 
regarding potential adverse health effects of unmetabolised folic acid in the circulation arising 
through high folic acid exposures from supplements and fortified foods.  Traditionally this 
related to the potential risk that long-term exposure to high dose folic acid might mask the 
anaemia of vitamin B12 deficiency in older people and allow the associated irreversible 
neurological symptoms to progress, but this is no longer considered to be a public health 
issue(1). A more recent concern has arisen from reports that the presence of unmetabolised folic 
acid in plasma in elderly people with low vitamin B12 status is associated with worse cognitive 
performance compared to those with low B12 status and no detectable folic acid in the 
circulation(109); some subsequent studies have not been able to confirm such findings and 
therefore this issue remains somewhat controversial(1). Other evidence suggested that folic acid 
doses in excess of 1mg/d could potentially promote the growth of undiagnosed colorectal 
adenomas in those with pre-existing lesions(110). However one recent meta-analysis (involving 
50,000 individuals) concluded that folic acid supplementation neither increased nor decreased 
site-specific cancer within the first 5 years of treatment(111). One recent study from this centre 
investigated the effects on circulating unmetabolised folic acid concentrations, in pregnant 
women and their newborns, of folic acid supplements at a dose of 400 µg/d continued beyond 
the period of pregnancy currently recommended (i.e. to the end of trimester 1). On the basis 
that folic acid intervention improved maternal and neonatal folate status(9), but did not cause 
higher concentrations of unmetabolised folic acid(112), it was concluded that there was no 
adverse impact from the exposure of pregnant women to 400 µg/d supplemental folic acid, over 
and above typical intakes through fortified foods. It remains to be confirmed however whether 
plasma unmetabolised folic acid arising from higher folic acid intakes is a cause for concern. 
In the meantime, given the uncertainty regarding the long term effects of exposure to high dose 
folic acid, it is important to avoid population-wide chronic exposures to folic acid at levels 
higher than are necessary, with evidence that beneficial effects are likely to be achievable at 
low intakes(90).   
In summary, it is unlikely that there are adverse effects associated with the presence of 
unmetabolised folic acid in the circulation at the generally low concentrations arising through 
food fortification. Indeed an expert international panel tasked with reviewing all aspects of 
folate biology and biomarkers recently concluded that it was ‘not aware of any toxic or 
abnormal effects of circulating folic acid’ even from much higher exposures than those 
obtained by food fortification(1). The risk-benefit debate surrounding food fortification with 
folic acid is continuing among scientists and policymakers, but the balance of evidence at this 
time appears to indicate that the proven benefits of folic acid fortification would more than 
outweigh any potential risks. 
 
Vitamin B12 
Low status of B12 is associated with a higher risk of cognitive dysfunction, 
cardiovascular disease and osteoporosis(70,113).  There are however important public health 
considerations in relation to vitamin B12.  First, the ability to achieve optimal B12 status in 
practice can be problematic for older people even with high dietary B12 intakes. Second, 
accurately assessing vitamin B12 status, and thus detecting deficient and low status, is difficult.  
A severe form of vitamin B12 deficiency arises in pernicious anaemia. This is an 
autoimmune gastritis characterised by profound B12 malabsorption owing to loss of intrinsic 
factor, leading to haematological signs (megaloblastic anaemia) and irreversible neurological 
disease which is fatal if untreated(114).  Once diagnosed, clinical deficiency is readily treatable 
with regular B12 injections delivered intramuscularly.  A much more subtle depletion of 
vitamin B12 arises as a result of food-bound B12 malabsorption from mild atrophic gastritis 
which diminishes gastric acid production (i.e. hypochlorhydria). This in turn reduces B12 
absorption from food because of the essential role of gastric acid in the release of B12 from 
proteins in the food matrix(115).  Food-bound B12 malabsorption commonly occurs in older 
adults, reported to affect up to 20%(114),  and leads to sub-clinical deficiency, where there is 
metabolic evidence of deficiency but without the classical haematological or neurological 
signs(116).  Thus the low B12 status found in older adults is primarily the result of food-bound 
B12 malabsorption related to atrophic gastritis rather than inadequate dietary intake(113).  
Similarly, the use of proton pump inhibitors or other gastric acid suppressant drugs can lower 
B12 status through malabsorption owing to hypochlorhydria(113)  
Accurate assessment of vitamin B12 status in order to identify and correct low or 
deficient status is problematic(117). Up to 4 biomarkers are used to assess B12 status, both direct 
(total B12 and holotranscobalamin; holoTC) and functional (homocysteine and methylmalonic 
acid; MMA), but each of these has limitations. Serum total vitamin B12 is the standard test 
used in clinical settings, with deficiency typically identified as B12 concentrations <148 
pmol/L. On the basis that 80% of total vitamin B12 concentrations is metabolically inert, the 
measurement of HoloTC has attracted much interest in recent years because it represents the 
metabolically active fraction of B12 available for cellular processes. HoloTC shows promise 
as a reliable biomarker of vitamin B12 status, but the influence of confounding factors needs 
to be more fully explored(117). Measurement of metabolites of vitamin B12-dependent reactions 
can also provide useful functional indicators of B12 status. With B12 depletion, the activity of 
B12-dependent enzyme methionine synthase will be impaired leading to an elevation of total 
homocysteine that can be readily measured in plasma. Plasma homocysteine is however not 
specific to vitamin B12 as it is influenced by folate, other B vitamins and non-nutrient factors 
including renal function, limiting its use as a biomarker of B12 status(117). Vitamin B12 
depletion also leads to reduced activity of methylmalonyl CoA mutase and an accumulation of 
the by-product MMA which can be measured in plasma. Measurement of MMA, unlike 
homocysteine, provides a specific biomarker for vitamin B12. Serum MMA is invariably 
elevated in patients with B12 deficiency and it also provides a useful biomarker of B12 status 
in population-based studies(118).   
In summary, accurate assessment of vitamin B12 is problematic and there is no 
consensus as to the best biomarker to use in clinical or research settings. It is now recommended 
that more than one biomarker be used to accurately diagnose B12 deficiency, and recently 
approaches that identify deficient status using combinations of two or more biomarkers have 
emerged(117). Ensuring that vitamin B12 deficiency is diagnosed and treated in patients, and 
B12 status optimised in older populations generally, should be prioritised in order to ensure 
that any adverse health consequences of deficient and low B12 status are prevented.  
 
Riboflavin and its metabolic interaction with vitamin B6  
Riboflavin, in its cofactor forms flavin mononucleotide (FMN) and flavin dinucleotide 
(FAD), is essential for numerous oxidation-reduction reactions and plays a fundamental role in 
the metabolism of energy, certain drugs and toxins and in supporting cellular antioxidant 
potential(119,120). Riboflavin-dependent metabolism involves interaction with a number of other 
nutrients. Riboflavin deficiency in animals is associated with impaired iron absorption, whilst 
riboflavin supplementation in humans was shown to enhance circulating haemoglobin 
concentrations and improve the response of iron deficiency anaemia to iron therapy(121).  In 
addition, riboflavin involves close metabolic interaction with vitamin B6, in that it is required 
(as FMN) for the generation of pyridoxal 5’ phosphate (PLP; the active vitamin B6 coenzyme 
form) in tissues from pyridoxine phosphate by pyridoxine-phosphate oxidase (PPO). Animal 
studies show that PPO activity is sensitive to changes in dietary riboflavin intake, with evidence 
that riboflavin deficiency can alter PLP levels(122). In humans, research from our centre 
demonstrated the metabolic dependency of vitamin B6 on riboflavin by showing that 
supplementing older adults with riboflavin not only improved biomarker status of riboflavin, 
but also led to a significant increase in blood PLP concentrations(123). 
As described earlier in this review, emerging evidence points to a novel role of 
riboflavin as an important modulator of blood pressure specifically in genetically at-risk 
individuals owing to the 677C→T polymorphism in MTHFR(31).  The precise biological 
mechanism explaining this novel gene-nutrient interaction in blood pressure is unclear at this 
time, however, MTHFR activity in people with the TT genotype appears to be particularly 
sensitive to riboflavin status(45). One could speculate that people with the variant TT genotype 
who have optimal riboflavin status may have a higher capacity to replace inactivated enzyme 
than TT genotype individuals with low riboflavin status. Alternatively, a higher riboflavin 
status may prevent the FAD cofactor from leaving the active site or may allow its quick 
replacement, thus stabilising the variant form of the enzyme. Overall the evidence indicates 
that these genetically at-risk adults have higher riboflavin requirements in order to sustain 
normal MTHFR activity although this remains to be specifically demonstrated(45,47).  
On the limited evidence available, riboflavin deficiency is a significant problem in 
developing countries(124).  Across the developed world also, sub-optimal riboflavin status may 
be widespread, but this is largely undocumented as biomarker status is rarely measured in 
population-based studies(125). The UK is in fact one of the very few countries worldwide to 
have included a riboflavin biomarker as part of its rolling NDNS survey(126).  Much more 
recently Ireland, in its National Adult Nutrition Survey (NANS), has measured biomarker 
status of riboflavin for the first time on a population-wide basis and the results are in close 
agreement with those of NDNS(126,127). 
In the British and Irish population-wide nutrition surveys, biomarker status of riboflavin 
was measured using erythrocyte glutathione activation coefficient (EGRac), widely accepted 
as the gold-standard measure of status(128). This coefficient is expressed as the ratio of the 
activity of the enzyme glutathione reductase in lysed red cells with and without addition of the 
cofactor FAD. EGRac, therefore, is a measure of glutathione reductase enzyme saturation with 
its riboflavin-derived cofactor; a low coefficient is generally considered to be normal, while 
higher values are indicative of suboptimal riboflavin status, although there is no universal 
agreement as to the cut-off points indicative of deficient and low status. Advantages of EGRac 
include stability and high sensitivity to small degrees of cofactor desaturation, while the lack 
of accessibility of this assay worldwide and very specific pre-analysis processing (including 
the need for washed red blood cells) makes this assay unfeasible in many settings(128).  Concern 
has been expressed regarding the large proportion of adults, as assessed in both the British and 
Irish population-based surveys, showing low biomarker status of riboflavin using EGRac. The 
functional significance of such findings is unclear however since in general, with the exception 
of younger women, mean dietary riboflavin intakes of British and Irish adults compared 
favourably with dietary reference ranges(126,127). Elsewhere in the world (including Canada and 
US), the situation is much less clear as riboflavin biomarkers are not measured (by any method) 
in nutrition surveys.  
In summary, on the limited available evidence, sub-optimal riboflavin status appears to 
be a more widespread problem than is generally recognised across the world because of the 
current reliance on dietary data only in nutrition surveys, without corresponding information 
on riboflavin biomarker status. There is a need to measure riboflavin biomarkers in population 
surveys, and to demonstrate the functional, gene-nutrient and health effects of riboflavin across 
the range of values, from deficient to optional biomarker status. 
 
 
Summary and Conclusions 
The health impacts, challenges and research priorities in relation to folate and related B vitamin 
status at key stages of lifecycle were reviewed using case studies to illustrate the roles of these 
vitamins in early, middle and late life (Table 1). To summarise:  
Optimal maternal folate status prevents megaloblastic anaemia in mothers during 
pregnancy and protects against the occurrence of NTD in the child. Folic acid, the vitamin form 
found in fortified foods and supplements, provides a highly bioavailable source of folate. Folic 
acid supplementation as a policy to prevent NTD has however proven to be largely ineffective 
in the UK, Ireland and elsewhere in Europe primarily because women typically start taking 
folic acid after the period of neural tube closure (3rd to 4th week of pregnancy) when folic acid 
is protective.  Apart from preventing NTD, the human in utero environment may influence 
offspring brain health in the longer term via DNA methylation, which is dependent on an 
adequate supply of folate, but this aspect requires further investigation. 
Optimal riboflavin status is required for the generation of the active form of B6 (PLP) 
in tissues, with some evidence that riboflavin may be the more limiting nutrient in humans with 
low PLP concentrations. Suboptimal riboflavin may be a widespread problem in all populations 
worldwide, but this is not well recognised because riboflavin status biomarkers are rarely 
measured. A novel gene-nutrient interaction, involving riboflavin and MTHFR has emerged in 
recent years, with important effects on blood pressure. Emerging evidence shows that targeted 
riboflavin supplementation could offer a personalised, non-drug treatment to lower blood 
pressure and improve blood pressure control in hypertensive patients with the variant MTHFR 
677TT genotype. In a wider public health context, sub-populations worldwide with this 
genotype may benefit from optimising riboflavin status to prevent or delay the development of 
high blood pressure in middle age. This in turn could potentially reduce the risk of stroke; 
however, large clinical trials are required to investigate effects on stroke and other disease end-
points.  
Folate and vitamin B12 are particularly important in later life because they are essential 
for the brain to support numerous central nervous system methylation reactions involving 
neurotransmitter and membrane phospholipid synthesis and myelin methylation. Subclinical 
deficiencies of these and related B vitamins are implicated in cognitive decline and depression 
in older adults, while optimal B vitamin status may help in maintaining better brain health in 
ageing. Well-designed randomised trials are required to confirm whether improving B-vitamin 
status can achieve better mental and cognitive health in older adults.  Any intervention with B 
vitamins is likely to be most effective before overt signs of neuropsychiatric disease has 
occurred and in people with low B vitamin status. Given some concerns regarding potentially 
harmful effects of folic acid at high exposure levels in older people with low vitamin B12 
status, future trials should investigate the effects of intervention at low-dose intakes.  
In conclusion, there are important health impacts of folate and metabolically related B 
vitamins through the lifecycle. There are also significant public health challenges to be 
overcome in order to achieve optimal status, and thus potentially prevent folate-related disease 
at a population level. For governments worldwide considering the relevant policy issues, there 
is a need for a balanced approach, and an emphasis on maintaining an optimal status of all 
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Figure Legends 
Figure 1. (Colour online) Overview of B vitamins in One-carbon Metabolism. Abbreviations. 
DHF, dihydrofolate; DHFR, dihydrofolate reductase; DMNT, DNA methyltransferases; dTMP, 
deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; MTHFR; 
methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; THF, tetrahydrofolate. (Adapted from Linus Pauling Institute at 
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Table 1.  Health impacts and challenges in relation to folate and related B vitamins at key stages of the lifecycle 
 Health Impact  Strength of 
Evidence  
Challenge or Research Gap 
 




• Peri-conceptional folic acid use by 
mothers protects against the occurrence of 
NTD in the child.  
 
 
• Maternal folate may influence brain 
development and subsequent cognitive 









Women typically start taking supplements after the 
period of neural tube closure when folic acid is 
protective. Mandatory folic acid food fortification is 
highly effective but controversial. 
 
More epigenetic studies needed to investigate effect 
of folic acid in humans. 
 
Riboflavin in middle life 
 
• Optimal riboflavin is required to generate 
the active form of B6 (PLP) in tissues  
 
• Riboflavin interacts with MTHFR within 
one-carbon metabolism to influence blood 
pressure 
 
• Supplemental riboflavin can lower blood 
pressure if targeted  at adults genetically at 
risk of developing hypertension owing to 











Sub-optimal riboflavin status occurs more 
commonly than is generally recognised. 
 
Mechanistic studies needed to explain role of 
MTHFR in blood pressure and modulating effect of 
riboflavin.  
 
More RCTs needed to investigate effect of riboflavin 
in genetically at risk adults with and without existing 
hypertension and in pregnancy. 
 
Folate, vitamin B12 and 
related B vitamins in 
later life   
 
 
• Folate and B12 essential for functioning of 
central nervous system 
 
• Optimal B vitamin status may help in 







More RCTs needed to confirm whether improving 
B-vitamin status can achieve better mental and 
cognitive health in older adults.  Such trials should 
target those with suboptimal B vitamin status and 
test effects of low-dose B vitamin intervention. 
 
